Cilazapril hydrochloride
Based on 1 publication(s) in Google Scholar
Cilazapril hydrochloride is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril hydrochloride reduces plasma ACE activity. Cilazapril hydrochloride can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure.
For research use only. We do not sell to patients.
- CAS No.: 88824-78-6
- Formula: C22H32ClN3O5
- Molecular Weight:453.96
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cilazapril hydrochloride
More
Biological Activity
Cilazapril (0.1-0.3 mg/kg orally) hydrochloride dose-dependently reduces plasma ACE activity and the pressor response to angiotensin in cats[1].
Cilazapril (10 mg/kg orally twice daily for 3.5 days) hydrochloride gradually reduces blood pressure in dogs with volume-depleted renal hypertension.
Cilazapril (10 mg/kg; p.o.; 2 weeks) hydrochloride decreases blood pressure, reduces heart weight to body weight ratio, and improves postischemic myocardial function in hyperthyroid rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 88824-78-6
-
Molecular Weight 453.96
-
Formula C22H32ClN3O5
-
SMILES
OC([C@H]1N2N(CCC[C@@H](C2=O)N[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCC1)=O.Cl
-
Synonyms
Ro 31-2848 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
[1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. [Content Brief]
[2]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39. [Content Brief]
[3]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15. [Content Brief]
[4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24. [Content Brief]
[5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cilazapril hydrochloride Related Classifications
HY-A0043B Related Classifications
Powered by Bioz